The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis in phase I and II studies.

WHOI scientists worked with WHOI engineers to modify and outfit baby grey seals with heart monitors ... are showing promise, sending back EKG readings, the duration between heart beats, and ...